MedPage Today) — SAN FRANCISCO — Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC), according…
Immunotherapy-TACE Regimen Boosts PFS in Unresectable Liver Cancer

Leave a Comment Leave a Comment
